GTGalina V. Trunova

Galina V. Trunova

*This is an algorithmically generated author record based on publicly available information.

Galina V. Trunova has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • PLGA Nanoparticles for Delivery of Antitumor Agents

    by E.R. Nemtsova, O.A. Bezborodova, G.V. Trunova, N.B. Morozova, A.D. Plyutinskaya, M.S. Vorontsova, Yu.B. Venediktova, V.A. Khokhlova, D. M Goshina, V.YU. Kan, et al.

    This paper presents a non-systematic review of the scientific literature focused on the study and application of nanoparticles based on the copolymer of lactic and glycolic acids (PLGA) as nanocarriers of antitumor drugs. It examines methods of manufacturing PLGA nanoparticles, their physicochemical properties which determine the accumulation of drugs, and biological properties which play an important role in the targeted delivery of antitumor drugs (passive or active). The mechanisms of passive targeting and methods of modifying the surface of nanoparticles for active targeting of drugs to tumor cells are discussed indicating possible methods of usage of PLGA nanoparticles (solid and gel-like) for patients’ treatment. The authors list main disadvantages of PLGA nanoparticles that hinder active translation of antitumor drugs inserted into nanocarriers to clinical practice. The review contains FDA recommendations from the program for study the quality of nanocarriers, including generics, with a view to ensure their transfer to clinical trials.

  • Open Access

    Virulence and tissue tropism of different epidemiologically significant SARS-CoV-2 variants for golden Syrian hamsters

    by Anastasiia V. Gracheva, Andrey O. Drokov, Daria I. Smirnova, Darya M. Khokhlova, Ekaterina R. Korchevaya, Andrey A. Pankratov, Galina V. Trunova, Varvara A. Khokhlova, Maria S. Vorontsova, Irina A. Leneva, et al.

    Introduction. Animal models for SARS-CoV-2 infection, reproducing the clinical features of COVID-19 in humans, are important tools for studying the pathogenesis of the disease, transmission of the pathogen and are indispensable for testing antiviral drugs and vaccines. The aim of the study was to assess the virulence and tissue tropism for golden Syrian hamsters of SARS-CoV-2 strains belonging to different epidemiologically significant variants: Wuhan-like, Delta, Omicron BA.1.1 and Omicron BA.5.2. Materials and methods. Hamsters were intranasally infected with different SARS-CoV-2 strains. Virulence and tissue tropism of SARS-CoV-2 strains were assessed by comparing the dynamics of weight, viral load in organs and histopathological changes in lungs in infected and uninfected animals. Results. The Wuhan-like Dubrovka strain had the greatest virulence for hamsters, which was manifested by the development of severe pneumonia and a delay in weight gain by 14.6%, high virus content in the lungs, nasal passages and brain — 6.2, 5,9 and 3.7 lg TCID50/ml of homogenate, respectively. Presumably, it was the infection of the Wuhan-like virus of the central nervous system that negatively affected the weight and general condition of the animals. When hamsters were infected with viruses belonging to the Delta and Omicron variants, the observed minor weight loss in animals was uninformative, so indicators such as lung histopathology, viral load in the lungs, nasal passages, heart and other organs played a decisive role in assessing the virus pathogenicity. A score assessment of lung histopathology was of particular value in assessing the severity of pneumonia, since it reduced subjectivity in evaluating the results of histological examination and provided a semi-quantitative assessment of the pathological process. Conclusion. Despite the revealed lower virulence for hamsters of viruses belonging to the Delta and Omicron variants compared to the ancestral Wuhan virus, this animal model for COVID-19 retains its value for conducting preclinical trials of antiviral drugs.


  • Open Access

    Single intranasal immunization with attenuated Wuhan-like SARS-CoV-2 provides highly effective cross-protection against Delta and Omicron variants of concern

    by Evgeny B. Faizuloev, Anastasiia V. Gracheva, Ekaterina R. Korchevaya, Yulia I. Ammour, Daria I. Smirnova, Darya M. Khokhlova, Andrey O. Drokov, Andrey A. Pankratov, Galina V. Trunova, Varvara A. Khokhlova, et al.

    Introduction. Despite the end of the COVID-19 pandemic, the problem of vaccine prevention of this disease appears highly relevant. The emergence and widespread distribution of the Omicron SARS-CoV-2 variant of concern (VOC) and its sublineages has dramatically reduced the efficacy of vaccination. The possible approach to solving this problem is to develop a nasal live attenuated vaccine capable of activating humoral, mucosal, and cell-mediated immunity, providing a prolonged immune response and cross-protection against different VOCs. The aim of the study was to determine the immunization efficacy with attenuated cold-adapted Wuhan-like SARS-CoV-2 D-D2 strain against homologous and heterologous challenges. Materials and methods. The study was conducted on an animal model of coronavirus pneumonia in golden Syrian hamsters. The efficacy of immunization was assessed by comparing the dynamics of weight, viral load in organs and histopathological changes in the lungs in immunized and unimmunized animals. Results. Single intranasal immunization of golden Syrian hamsters with D-D2 strain showed its high immunogenicity: seroconversion was evident in all immunized animals. Wuhan-like D-D2 strain provides highly effective protection of hamsters against the development of productive infection and pneumonia when challenged both with ancestral virus and heterologous strains related to Delta (AY.122) and Omicron (sublineages BA.1.1 and BA.5.2) variants. Conclusion. SARS-CoV-2 attenuation is a promising strategy for the development of a highly effective nasal live COVID-19 vaccine.


  • Open Access

    Ascite-solid model of prostate cancer and its morphological characteristics

    by E. A. Plotnikova, N. B. Morozova, A. V. Ryabova, G. V. Trunova, V. A. Khokhlova, V. B. Loschenov, A. A. Pankratov, A. D. Kaprin

    Targeted therapy and immunotherapy are considered promising novel therapies capable of increasing the effcacy of prostate cancer (PCa) treatment. The purpose of the study was to obtain and characterize TRAMP-C2 subcutaneous and ascite-solid models of prostate cancer in C57Bl/6j mice to study specifc anti-tumor activity of the candidate molecules of targeted drugs and adjust immunotherapy strategies in an evidence-based manner. Material and Methods. We used cultured TRAMP-C2 cells in subcutaneous and ascites mouse prostate cancer models. Histological and immunohistochemical methods were used to study the tumor tissues. Results. The high in vivo growth ability of TRAMP-C2 cells was demonstrated in subcutaneous and intraperitoneal inoculation of C57Bl/6j mice. These tumors are characterized by a high reproducibility and level of PSMA expression. Histological study showed that subcutaneous and carcinomatous TRAMP-C2 tumor nodules had solid structure morphologically corresponding to low differentiated neoplasm, cytomorphological analysis of smears showed that peritoneal fuid containd a large number of rounded tumor cells, macrophages and erythrocytes. Conclusion. The obtained subcutaneous and ascite-solid models of TRAMP-C2 can be useful for the development of new ways to effectively treat cancer, including targeted and immunotherapy, as well as for the experimental study of biotherapeutic effects using PSMA as a target, and photoinduced effects.

  • Open Access

    Comparative study of Wuhan-like and omicron-like variants of SARS-CoV-2 in experimental animal models

    by I A Leneva, D I Smirnova, N P Kartashova, A V Gracheva, A V Ivanina, E A Glubokova, E R Korchevaya, A A Pancratov, G V Trunova, V A Khokhlova, et al.

    Introduction. The variability of SARS-CoV-2 appeared to be higher than expected, the emergence of new variants raises concerns. The aim of the work was to compare the pathogenicity of the Wuhan and BA.1.1/Omicron variants in BALB/c mice and Syrian hamsters. Materials and methods. The study used strains of SARS-CoV-2: Dubrovka phylogenetically close to Wuhan-Hu-1, and LIA phylogenetically close to Omicron, BALB/c mice, transgenic mice B6.Cg-Tg(K18-ACE2)2Prlmn/HEMI Hemizygous for Tg(K18-ACE2)2Prlmn, Syrian golden hamsters. Animals were infected intranasally, pathogenicity was estimated by a complex of clinical, pathomorphological and virological methods. Results. Comparative studies of SARS-CoV-2 Dubrovka and LIA strains on animal models demonstrated their heterogeneous pathogenicity. In parallel infection of BALB/c mice with Dubrovka and LIA variants, the infection proceeded without serious clinical signs and lung damage. Infection with the LIA strain resulted to a systemic disease with a high concentration of viral RNA in the lungs and brain tissues of animals. The presence of viral RNA in mice infected with the Dubrovka strain was transient and undetectable in the lungs by day 7 post-infection. Unlike the mouse model, in hamsters, the Dubrovka strain had a greater pathogenicity than the LIA strain. In hamsters infected with the Dubrovka strain lung lesions were more significant, and the virus spread through organs, in particular in brain tissue, was observed. In hamsters infected with the LIA strain virus was not detected in brain tissue. Conclusion. The study of various variants of SARS-CoV-2 in species initially unsusceptible to SARS-CoV-2 infection is important for monitoring zoonotic reservoirs that increase the risk of spread of new variants in humans.